Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisCharles V. Pollack, Jeffrey I. Weitz, Bushi Wang et al.|New England Journal of Medicine|2017Cited by 1.1k
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationOliver Grottke, John W. Eikelboom, James Aisenberg et al.|Critical Care|2016Cited by 47
Improving acute pain management in emergency medicineCharles V. Pollack, Eugene R. Viscusi|Hospital Practice|2015Cited by 13
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ studyCharles V. Pollack, Jeffrey I. Weitz, Richard A. Bernstein et al.|Journal of Medical Economics|2016Cited by 11
INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONSCharles V. Pollack, CW Kam, John W. Eikelboom et al.|Emergency Medicine Journal|2015Cited by 7